Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib After Failure of First-Line ICI-Based Combination Therapy in Child-Pugh B HCC (RECOMEND)
KCT0011646Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in hepatocellular carcinoma (HCC), hepatic failure, sponsored by Boryung. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)hepatic failure
Beyond the preview
Go deeper on KCT0011646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011646.